Androgen replacement therapy and prostate cancer
Beuzeboc, P.; Richaud, P.
Progres en Urologie Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(5 Suppl 2: 1276-1277
2003
ISSN/ISBN: 1166-7087 PMID: 15816405 Document Number: 557534
Document emailed within 1 workday
Related Documents
Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J.; Cleutjens, K.; Noordzij, A.; Visakorpi, T.; Kallioniemi, O.P. 1997: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Research 57(2): 314-319Roux, C. 2003: Osteoporosis due to androgen suppression therapy in men with prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(2 Suppl 1: 24-27
Buyyounouski, M.K. 2010: Androgen deprivation therapy in high-risk prostate cancer Oncology 24(9): 806; 809
Arai, G.; Okada, H. 2016: Androgen deprivation therapy for prostate cancer: adverse effects and their management Nihon Rinsho. Japanese Journal of Clinical Medicine 74(Suppl 3): 605-609
Pettaway, C.A. 1999: Racial differences in the androgen/androgen receptor pathway in prostate cancer Journal of the National Medical Association 91(12): 653-660
Alvarez Rodríguez, S.; Alonso Gordoa, T.; Burgos Revilla, F.Javier. 2018: Current status of androgen deprivation therapy in hormone-sensitive prostate cancer Archivos Espanoles de Urologia 71(3): 247-257
Ying, J.; Yao, D.-H.; Ren, X.-M. 2003: Study of sexual hormone changes in prostate cancer patients before and after androgen deprivation therapy Zhonghua Nan Ke Xue 9(3): 191-192; 196
Hu, Y.-H.; Guo, J.-C.; Zhang, M. 2017: Bipolar androgen therapy: a novel therapeutic strategy for castration-resistant prostate cancer Zhonghua Nan Ke Xue 23(12): 1138-1140
Izbicka, E.; MacDonald, J.R.; Davidson, K.; Lawrence, R.A.; Gomez, L.; Von Hoff, D.D. 1999: 5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells Anticancer Research 19(2a): 1285-1291
Bastos, D.A.; Dzik, C.; Rathkopf, D.; Scher, H.I. 2014: Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer Oncology 28(8): 693-699
Amler, L.C.; Agus, D.B.; LeDuc, C.; Sapinoso, M.L.; Fox, W.D.; Kern, S.; Lee, D.; Wang, V.; Leysens, M.; Higgins, B.; Martin, J.; Gerald, W.; Dracopoli, N.; Cordon-Cardo, C.; Scher, H.I.; Hampton, G.M. 2000: Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1 Cancer Research 60(21): 6134-6141
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
2015: (P063) Can Some High-Risk Prostate Cancer Patients Be Treated With a Shorter Course of Androgen Deprivation Therapy (ADT)? Oncology 29(4 Suppl. 1)
Ziaran, S.; Goncalves, F.M.; Wendl, J.; Trebaticky, B.; Breza, J.S. 2009: Evaluation of bone mass density on patients with prostate cancer prior to the start of androgen deprivation therapy Bratislavske Lekarske Listy 110(9): 559-562
Pickles, T.; Pollack, A. 2006: The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancer Canadian Journal of Urology 13(Suppl 2): 68-71
Sweeney, C.J. 2006: ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer Clinical Advances in Hematology and Oncology: H&o 4(8): 588-590
Akishita, M. 2007: Hormone replacement Up-to-date. Effects of androgen replacement therapy on vascular function and atherosclerosis Clinical Calcium 17(9): 1385-1391
Johnke, R.M.; Edwards, J.M.; Evans, M.J.; Nangami, G.N.; Bakken, N.T.G.; Kilburn, J.M.; Lee, T.-K.; Allison, R.R.; Karlsson, U.L.; Arastu, H.H. 2009: Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression In Vivo 23(5): 827-833
Gao, J.; Isaacs, J.T. 1998: Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells Cancer Research 58(15): 3299-3306
Jensen, C.F.S.; Fode, M.; Østergren, P.; Sønksen, J. 2017: Testosterone replacement therapy for hypogonadism in men with prostate cancer Ugeskrift for Laeger 179(9)